Cost-effectiveness of asthma therapy: A comprehensive review

Journal of Asthma

Volumn 52, Issue 6, 2015, Pages 529-537

  Domínguez Ortega, Javier ^a   Phillips Anglés, Elsa ^a   Barranco, Pilar ^a   Quirce, Santiago ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Asthma treatment; cost effectiveness; cost utility; QALY; work productivity

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; LEUKOTRIENE; OMALIZUMAB; SALMETEROL; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT;

ARTICLE; ASTHMA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE SEVERITY; EMERGENCY CARE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; IMMUNOTHERAPY; JOB PERFORMANCE; LUNG FUNCTION; MODERATE PERSISTENT ASTHMA; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; COST OF ILLNESS; DESENSITIZATION; DRUG COMBINATION; ECONOMICS; HEALTH; SEVERITY OF ILLNESS INDEX;

ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; EFFICIENCY; GLOBAL HEALTH; HEALTH CARE COSTS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX;

EID: 84938904941     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2014.999283     Document Type: Article

References (62)

1. Executive Committee GEMA 2009. GEMA2009 (Spanish guideline on the management of asthma). J Investig Allergol Clin Immunol 2010;20:1-59.
2. Kim YM, Kim YS, Jeon SG, Kim YK. Immunopathogenesis of allergic asthma: more than the Th2 hypothesis. Allergy Asthma Immunol Res 2013;5:189-196.
3. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010;65:152-167.
4. Wechsler ME, Laviotte M, Rubin AS, Fiterman J, Lapa E Silva JR, Shah PL, Fiss E, et al. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132:1295-1302.
5. Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asia Pac Allergy 2014;4:75-85.
6. Price P, Fletcher M, Van der Molen T. Asthma control and management in 8.000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009.
7. Dal Negro RW, Michetto C, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respir Med 2007;101: 2511-19.
8. ToT, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP. Global asthma prevalence in adults: findings from crosssectional world health survey. BMC Public Health 2012;12:204.
9. Quirce S. Asthma in Alergologica 2005. J Investig Allergol Clin Immunol 2009;19:14-20.
10. Arnedo-Pena A, García-Marcos L, Bercedo-Sanz A, Aguinaga-Ontoso I, González-Díaz C, García-Merino A, Busquets-Monge R, et al. Prevalence of asthma symptoms in schoolchildren and climate in Western European countries: an ecological study. Int J Biometeorol 2013;57:775-784.
11. Carreras M, Garcia-Goñi M, Ibern P, Coderch J, Vall-Llosera L, Inoriza JM. Estimates of patient costs related with population morbidity: can indirect costs affect the results? Eur J Health Econ 2011;12:289-295.
12. Patel MR, Nelson BW, Id-Deen E, Caldwell C. Beyond co-pays and out-of-pocket costs: perceptions of health-related financial burden in managing among African American women. J Asthma 2014; 51: 1083-1088.
13. Higgings JPT, Green S. Cochrane handbook for systematic reviews of interventions: current version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from: www.cochrane.org/handbook [last accessed 27 Nov 2014].
14. Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, Heinrich J, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013;160:93-101.
15. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med 2010; 103:98-106.
16. Rely K, McQuire SE, Alexandre PK, Escudero GS. Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children. Value Health 2011;14:S43-S47.
17. Martínez-Moragón E, Serra-Batlles J, De Diego A, Palop M, Casan P, Rubio-Terrés C, Pellicer C; por el Grupo de Investigadores del estudio AsmaCost. Economic cost of treating the patient with asthma in Spain: the AsmaCost study. Arch Bronconeumol 2009; 45:481-486.
18. Ojeda P, Sanz de Burgoa V; Coste Asma Study. Costs associated with workdays lost and utilization of health care resources because of asthma in daily clinical practice in Spain. J Investig Allergol Clin Immunol 2013;23:234-241.
19. Blasco Bravo AJ, Perez-Yarza EG, Lázaro Y de Mercado P, Bonillo-Perales A, Díaz-Vázquez CA, Moreno-Galdós A. Coste del asma en pediatría en España: un modelo de evaluación de costes basado en la prevalencia. An Pediatr (Barc) 2011;74:145-153.
20. Serra-Batlles J, Plaza V, Comella A. Changes in clinical, pulmonary function, quality of life and costs in a cohort of asthmatic patients followed for 10 years. Arch Bronconeumol 2011;47: 482-487.
21. Kauppi P, Linna M, Martikainen J, Makela MJ, Haahtela T. Followup of the Finnish Asthma Programme 2000-2010: reduction of hospital burden needs risk group rethinking. Thorax 2013;68: 292-293.
22. Martinez-Moragon E. Impacto económico y coste-efectividad del tratamiento del asma grave. In: Plaza Moral V, López Viña A, Quirce Gancedo S, ed. Asma grave y asma de control difícil. Programa Ulises. Madrid: Saned Grupo 2013;4:67-84.
23. Akibami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, Smith RA. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol 2012;129:49-64.
24. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
25. Rodriguez-Martinez CE, Nino G, Castro-Rodriguez JA. Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mildpersistent asthma. Pediatr Pulmonol 2014. [Epub ahead of print]. doi: 10.1002/ppul.23073.
26. Johansson G, Sondhi PM. Cost effectiveness analysis of salmeterol/fluticasone propionate 50/100 ug vs. fluticasone propionate 100ug in adults and adolescents with asthma III: results. Pharmacoeconomics 1999;16:15-21.
27. Andersson F, Stalhl E, Barnes PJ, Moller C, Arheden L. Adding formoterol to budesonide in moderate asthma - health economic results from the FACET study. Respir Med 2001;95: 505-512.
28. Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Costeffectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respir Med 2006;100: 586-594.
29. Fritscher L, Chapman KR. Seretide: a pharmacoeconomic analysis. J Med Econ 2008;11:555-570.
30. Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002;20:909-918.
31. Rosenhall L, Borg S, Andersson F, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. Int J Clin Pract 2003;57:662-667.
32. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Costeffectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006;24:695-708.
33. Quirce S, Barcina C, Plaza V, Calvo E, Muñoz M, Ampudia R, Capel M. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. J Asthma 2011;48:839-847.
34. Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones K, Lavorini F, Harris T, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclomethasone-formoterol: a retrospective study of real-world patients. Prim Care Respir J 2013;22:439-448.
35. Gerzeli S, Rognoni C, Quaglini S, Cavallo MC, Cremonesi G, Papi A. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig 2012;32:253-265.
36. Antoniu SA, Antohe I. Evaluation of inhaled tiotropium in asthma uncontrolled with standard combination therapy. Expert Opin Pharmacother 2013;14:967-969.
37. Albertson TE, Schivo M, Gidwani N, Kenyon NJ, Sutter ME, Chan AL, Louie S. Pharmacotherapy of critical asthma syndrome: current and emerging therapies. Clin Rev Allergy Immunol 2013. [Epub ahead of print]. doi:10.1007/s12016-013-8393-8.
38. Guyer AC, Long AA. Long-acting anticholinergics in the treatment of asthma. Curr Opin Allergy Clin Immunol 2013;13:392-398.
39. Adams KS, Lowe DK. Tiotropium for adults with inadequately controlled persistent asthma. Ann Pharmacother 2013; 47:117-123.
40. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vanderwalker M, Sigmund R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198-1207.
41. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Eng J Med 2010; 363:1481-1488.
42. Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting B-agonists. Appl Health Econ Health Policy 2014;12:447-459.
43. Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol 2014;14: 363-370.
44. Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, Willich SN. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008;101:316-324.
45. Reinhold T, Ostermann J, Thum-Oltmer S, Brüggenjürgen B. Influence of subcutaneous specific immunotherapy on drug costs in children suffering from allergic asthma. Clin Transl Allergy 2013;3:30.
46. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy 2012;67:1087-1105.
47. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115:459-465.
48. Nopp A, Johansson SG, Ankerst J, Palmqvist M, Öman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007;62:1175-1181.
49. D'Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C, Molino A, et al. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidiscip Respir Med 2014;9:23.
50. Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. Pharmacoeconomics 2012;30:991-1004.
51. Diaz RA, Charles Z, George E, Adler AI. NICE guidance on omalizumab for severe asthma. Lancet Respir Med 2013;1:189-90.
52. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265-269.
53. Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-1776.
54. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Costeffectivenes of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120: 1146-1152.
55. Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45-53.
56. Van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma. J Med Econ 2013;16:342-348.
57. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-153.
58. Costello RW, Long DA, Gaine S, McDonnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011;180:637-641.
59. Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843-848.
60. Menzella F, Facciolongo N, Piro R, Formisano D, Roggeri A, Simonazzi A, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4 year follow-up. Ther Adv Respir Dis 2012;6: 87-95.
61. Levy AN, Ruiz J, Garcia A, Soler Garcia-Agua N, Sanjuan Hidalgo MV. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma 2014. [Epub ahead of print]. doi:10.3109/02770903.2014. 941474.
62. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65:1141-1148.